During a period of widespread illness, access to certain medications became unexpectedly restricted in some states, particularly those led by Democratic governors. The decisions sparked intense debate and accusations of prioritizing pharmaceutical interests over patient well-being, with some claiming these limitations contributed to preventable suffering and loss of life.
